1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
656F461DCFA137FEE652582160044743A
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-best-practices-biopharmaceutical-medical-publications-authorship-selection-criteria-process?opendocument
18
19opendocument
203.80.224.52
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Scientific Publications

Best Practices in Biopharmaceutical Medical Publications: Authorship Selection Criteria and Process

ID: 5492


Features:

5 Info Graphics

26 Data Graphics

160+ Metrics


Pages/Slides: 38


Published: 2018


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Best Practices in Biopharmaceutical Medical Publications: Authorship Selection Criteria and Process”

STUDY OVERVIEW

Scientific publications is a critical activity for the pharmaceutical industry - it is the principal way that physicians learn scientific/medical information about a company's existing and pipeline products. But biopharmaceutical companies sometimes encounter gray areas when it comes to authorship selection for articles.

Best Practices, LLC undertook benchmarking research to examine the industry's approach to authorship selection. In particular, this study reviews the standards, processes and rationale of critical authorship selection and retention decisions. Publications leaders can use this research to shape their publication policies to avoid uncertainties and delays.

KEY TOPICS

  • Criteria and Process for Different Types of Publications
  • Defining, Tracking, and Recording Author Contributions
  • Process for Internal vs. External Authors

KEY METRICS

  • Please clarify why you don't create an informal working group of trial contributors to oversee author determination
  • Please clarify why you don't have a separate process for author identification/selection for early research or R&D publications
  • Please clarify why you don't have a separate process for author identification/selection for HEOR publications
  • Who ultimately determines who will be invited to be an author?
  • What changes to the author list are allowed?
  • Who approves a change in authorship?

SAMPLE KEY FINDINGS

  • All use ICMJE authorship criteria but many go beyond it
    • All companies adhere to ICMJE, but 75 percent define “substantial” contributions and about half go beyond ICMJE.
    • Those who use only ICMJE consider its criteria fair, sufficient and comprehensive.

METHODOLOGY


Best Practices, LLC engaged 23 leaders from biopharmaceutical companies and a publication services consultancy in this benchmarking research.


Industries Profiled:
Pharmaceutical; Biopharmaceutical; Biotech; Manufacturing; Consumer Products; Diagnostic; Medical Device; Chemical; Health Care


Companies Profiled:
Abbvie; Akebia Therapeutics; Allergan; Alnylam Pharmaceuticals; Astellas; AstraZeneca; Bayer; Bioventus; Celgene; Daiichi Sankyo; Envision Pharma Group; Ferring Pharmaceuticals; Genentech; Heel; Johnson & Johnson; Merck; Novartis; Roche; Sanofi Genzyme; Shionogi Inc.; Shire; Takeda Pharmaceuticals


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.